THBS2, thrombospondin 2, 7058

N. diseases: 149; N. variants: 13
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1832661
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA
ANOPHTHALMIA AND PULMONARY HYPOPLASIA 		0.040 Biomarker disease BEFREE Combining data on levels of CA19-9 and CEA, CA19-9 and CA125, or CA19-9 and thrombospondin-2 increased the sensitivity of detection of PDAC but slightly reduced specificity. 31676359 2019
CUI: C1832661
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA
ANOPHTHALMIA AND PULMONARY HYPOPLASIA 		0.040 Biomarker disease BEFREE Methods: Prior to surgery plasma levels of thrombospondin-2 (THBS2), which was recently published as a novel biomarker, and CA19-9 from 52 patients with histologically proven PDAC were determined, circulating cell-free (cfDNA) was quantified. 30867830 2019
CUI: C1832661
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA
ANOPHTHALMIA AND PULMONARY HYPOPLASIA 		0.040 Biomarker disease BEFREE TSP-2 is a highly specific diagnostic marker and an independent prognostic marker in patients with PDAC. 30569296 2019
CUI: C1832661
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA
ANOPHTHALMIA AND PULMONARY HYPOPLASIA 		0.040 Biomarker disease BEFREE With a specificity of 98%, the combination of THBS2 and CA19-9 yielded a sensitivity of 87% for PDAC in the phase 2b study. 28701476 2017